Kawasaki disease is a self-limiting acute vasculitis that affects small and mediumsized vessels, and is the most common cause of acquired heart disease in children in our environment. Up to 25% of untreated patients develop coronary aneurysms.
Introduction
Kawasaki disease (KD) is a self-limiting acute vasculitis that affects blood vessels of small and medium calibre. At present, it is the leading cause of acquired heart disease in children in developed countries and the second most frequent cause of vasculitis in children following Henoch-Schönlein purpura. 1 Although the inflammatory process resolves spontaneously in most patients, up to 25% of untreated patients develop coronary artery complications, a proportion that decreases to approximately 4% in children treated with high-dose intravenous immunoglobulin (IVIG) through a mechanism that is yet unknown. 2, 3 It is suspected that an infectious agent may trigger the disease, but the causative agent has yet to be identified. 4 Kawasaki disease is most prevalent in Asian countries, especially in Japan, where the incidence has been increasing to up to 265 cases per 100 000 children aged less than 5 years 5 ; in the United States, the incidence is approximately 25 per 100 000 children aged less than 5 years, 6 and in Europe it ranges between 5.4 and 15 per 100 000 children aged less than 5 years. 7, 8 The overall incidence in Spain is unknown, but a recent study has described an incidence in Catalonia of 8 per 100 000 children aged less than 5 years 9 in the 2004---2013 period, similar to the incidence in the United Kingdom (8.4/100 000) 10 .
Of all cases, 85% occur in children aged less than 5 years, with the incidence peaking between 18 and 24 months of life. Kawasaki disease is less frequent in infants aged less than 3 months or more than 5 years, although children in these age groups are at higher risk of developing coronary artery aneurisms. The male-to-female ratio is 1.5:1. There is evidence that KD is more common in winter and spring. 11 The mortality of KD in Spain is not known, although mortality peaks between 15 and 45 days since onset of fever, when coronary artery vasculitis occurs concomitantly with significant elevation of the platelet count and a hypercoagulable state.
At present, a study known as KAWA-RACE is being conducted in Spain. It is a nationwide multicentre retrospective and prospective study of the epidemiological, clinical, laboratory and microbiological determinants of the response to treatment of KD and the risk of developing coronary aneurisms in patients aged less than 14 years. During the retrospective phase (2011---2016), the study included 625 patients. The results of this study, which have yet to be published at the time of this writing, will broaden our knowledge of KD in Spain.
Aetiology, pathogenesis and genetics
Although clinical and laboratory findings and the epidemiologic characteristics of the disease hint at an infectious cause or trigger, a specific aetiological agent has not been identified to date. Previous studies have also been unable to prove an association between the development of KD and exposure to certain drugs or the immune response to a superantigen. 12 One of the theories that is currently most widely accepted is that KD is caused by an infectious agent that is inhaled and infects medium-size ciliated bronchial epithelial cells. 13 Recent studies based on the analysis of the large epidemics of KD in Japan suggest that the causative agent could be an environmental agent borne by tropospheric winds, possibly a fungal toxin. 14 At the same time, the high incidence in Asian communities and the increased risk of siblings of cases suggest that host genetic factors are important in the pathogenesis of KD. A few genomewide association studies (GWAS) in patients with KD 11 have been published that identified several loci implicated in inflammation, the immune response and cardiovascular involvement. Thus, a reasonable hypothesis is that KD is caused by an infectious agent yet to be identified that produces disease only in genetically predisposed individuals, especially those of Asian descent. Its low incidence in the first months of life and in adults suggests that this is an agent to which adults have developed immunity and newborns are passively protected against thanks to maternal antibodies.
Diagnosis of disease
The diagnosis is based on clinical criteria and is supported by serum values of inflammatory markers ( Table 1 ). The identification of aneurisms in the coronary arteries or other locations confirms the diagnosis; however, coronary aneurisms are not usually detected until the first week from onset, so a normal echocardiographic examination early on does not rule out the diagnosis. 11 The diagnosis of atypical or incomplete KD should be considered in patients with prolonged fever of unknown origin that meet fewer than 4 of the main clinical criteria and have compatible laboratory or echocardiographic findings ( Fig. 1 ). 11 Infants aged less than 6 months are more likely to have prolonged fever with no additional manifestations of KD and are at higher risk of developing coronary complications.
Cardiovascular involvement in Kawasaki disease
Cardiovascular manifestations and complications (Table 2) are the main cause of morbidity and mortality in KD, both in the acute stage and in the long term. Patients experience inflammation at the level of the pericardium, myocardium, endocardium (including the heart valves) and the coronary arteries. Recent microscopy studies have identified 3 vasculopathic processes: the first is a self-limited process that ends about 2 weeks from onset, a necrotising arteritis produced by infiltration of activated neutrophils into the adventitia that causes aneurisms. The second process is a subacute/chronic vasculitis with infiltration of 3. If the echocardiogram is positive, treatment should be given within 10 days of fever onset or after the tenth day of fever in case of elevated acute phase reactants lymphocytes, plasma cells, eosinophils and macrophages that starts 2 weeks from onset and may continue for months or even years in some patients. The third is luminal myofibroblastic proliferation of the medial smooth muscle cells that starts in the first 2 weeks and persists for months or years and can eventually cause arterial stenosis. 15
Diagnosis of cardiovascular involvement Echocardiogram
Echocardiography is the gold-standard imaging test for the evaluation of the coronary arteries, ventricular function, pericardial/pleural effusion and valve regurgitation in the acute stage of KD. Table 3 proposes a protocol for cardiovascular assessment in KD that takes into account the abnormalities described most frequently in the current literature. 11, 16 Other imaging techniques
In general, routine use of transoesophageal echocardiography, coronary angiography, coronary magnetic resonance imaging or computerised axial tomography is not indicated for diagnosis or management of KD in the acute stage. In the acute stage in up to 25% of patients.
In the early course of KD, it is usually of moderate severity, and it does not appear to persist on follow-up. It has been correlated with other laboratory markers of inflammation Its development seems to be associated with the pancarditis or the shared inflammatory process that takes place during the acute stage of KD.
Aortic regurgitation
Much less frequent (1%) It is associated with aortic root dilation in the early course of illness, and has been reported in 10% of patients during the acute stage of KD. Its presence has been associated with coronary artery dilation Pericarditis 6---24% of patients In most patients it is limited to the acute stage of disease, and it is usually mild and transient.
In cases where there are limitations to the echocardiographic evaluation, for instance due to the presence of thrombi or stenosis, or in older children and/or adolescents in which the echocardiographic resolution is not adequate, performance of more advanced imaging tests could be indicated, especially in patients with serious abnormalities in the proximal part of the coronary arteries in whom it is necessary to examine the distal segments to make treatment decisions (Table 4 ). 17, 18 Electrocardiogram The inflammation at the cardiac level that occurs in the acute stage of KD involves mainly the coronary arteries, although there may also be clinical or subclinical myocardial inflammation that produces electrocardiographic changes indicative of myocardial and/or coronary artery involvement (Table 3) . 
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Treatment of KD in the acute stage
The first-line medical treatment in KD is intravenous immunoglobulin (IVIG) infusion therapy. 11 There is ample evidence of the efficacy of IVIG during the acute stage in reducing the incidence of coronary aneurisms. 19---21 Gamma globulin is a biologic drug consisting of a preparation with a high concentration of immunoglobulin G (≥95%) and other human immunoglobulins. Its mechanism of action remains unknown. It should be administered as early as possible within 10 days from onset, or even later in case of persistence of the fever of unknown origin, persistence of inflammatory activity as evinced by the elevation of CRP levels or the ESR, or presence of coronary aneurisms. The standard regimen is a single infusion of 2 g/kg of IVIG (Table 5) . 20, 22 Concomitant treatment with acetylsalicylic acid (ASA) 23 should be initiated, at a moderate dose (30---50 mg/kg/day every 6 h, administered orally) until the patient has been afebrile for 48---72 h, subsequently adjusted to a lower dose to achieve an antiplatelet effect ( 3 ---5 mg/kg/day in a single dose, administered orally) to be maintained through 6 ---8 weeks from onset and normalisation of the platelet count, acute phase reactant levels and echocardiographic features. In spite of its anti-inflammatory activity, it appears that treatment with ASA does not reduce the incidence of coronary aneurisms, however, in the studies that demonstrated the efficacy of IVIG it was used as adjuvant treatment, so ASA is traditionally associated with IVIG therapy. 24 Approximately 10---20% of patients with KD have persistent fever 36 h after treatment with IVIG and ASA. 25 In these patients, inflammation and the risk of coronary damage therefore persist.
The use of corticosteroids as primary adjuvant treatment remains controversial, but a growing number of studies support it. 26, 27 In a study in Japanese patients with KD with a score indicative of high risk of resistance to primary treatment with IVIG therapy, the addition of corticosteroids to IVIG and ASA was associated with a decrease in inflammation, improved coronary outcomes and a reduced duration of symptoms, 26 and the Japanese Circulation Society guidelines include steroid therapy as a first-line adjuvant treatment in these cases. 16 Tw o recent systematic reviews with meta-analyses have reported that corticosteroid therapy has proven effective in the prevention of coronary lesions, although the source studies were mainly conducted in Japanese patients. 28, 29 The Japanese scoring systems have not been validated in populations in our region or in the United States. 30 The American Heart Association considers the use of a long course of steroids concomitant with IVIG therapy in patients with risk factors for IVIG resistance, and administration of highdose methylprednisolone boluses as adjuvant treatment in patients that do not respond to the initial or repeated dose of IVIG or concomitantly to the second dose of IVIG in patients that do not respond to initial IVIG therapy combined with a long course and taper of oral steroids. 11 Corticosteroids may be considered for prophylaxis in children with severe KD and as rescue therapy in patients that do not respond to initial treatment. However, the routine use of corticosteroid therapy in all patients with KD needs to be supported by further research, especially outside Japan.
There is evidence that biological therapy with infliximab, a monoclonal antibody specific for tumour necrosis factor alpha (TNF␣), is efficacious in reducing inflammation, but not in suppressing vasculitis. 31 Its use as adjuvant therapy to first-line treatment seems safe, but does not improve coronary outcomes.
The current evidence is not conclusive as regards the management of patients resistant to the initial IVIG dose. Many experts recommend a second dose of IVIG, although clinical trials have yet to be performed to assess the efficacy of this approach. 3 Corticosteroid therapy has also been used 
Corticoids
Various regimens: -Methylprednisolone, 30 mg ---1 /kg/day IV for 3 days, followed by methylprednisolone, prednisolone or prednisone 2 mg/kg/day IV or p.o. with gradual taper based on patient evolution (Fig. 2) -Methylprednisolone 2 mg/kg/day IV until fever resolves and CRP levels decrease, with gradual taper based on patient evolution (Fig. 2 as second-line treatment in these patients, as noted above. It appears that long courses of oral corticosteroids may suppress vascular inflammation, but there have been no clinical trials comparing different corticosteroid regimens. Tw o retrospective studies and one randomised multicentre study have compared the use of infliximab in patients resistant to IVIG to administration of a second dose of IVIG. 32 Treatment with infliximab was associated with a reduction in length of stay and in the duration of fever, but not in the incidence of cardiovascular sequelae or adverse events. There are 3 published case reports describing the successful use of anakinra, an interleukin-1 (IL-1) receptor antagonist, in patients with KD highly refractory to conventional treatment, and clinical trials that evaluate its efficacy in acute KD are currently underway. 33---36 Anakinra has been associated with a decrease in the duration of fever and serum marker levels as well as improved shortterm coronary outcomes, so its use should be considered for rescue of patients that do not respond to conventional treatment.
Ciclosporin seems to reduce the length of stay and duration of fever, but not the incidence of coronary complications. A clinical trial of ciclosporin in combination with IVIG is currently in progress. 37 Cyclophosphamide, which is widely used to treat other types of vasculitis, should be reserved for very severe cases on account of its side effects, as should plasma exchange.
There are cases where diagnosis is delayed (past 10 days from onset) and the fever and elevation of acute phase reactants have already resolved. In these cases, treatment with low-dose ASA for an antiplatelet effect ( 3 ---5 mg/kg/day) should be initiated and maintained until the end of the acute stage of disease ( 6 ---8 weeks), verifying the normalisation of echocardiographic features and platelet count before discontinuation.
Based on the current evidence, this consensus document proposes different treatment regimens according to the presence of risk factors at diagnosis, the clinical condition of the patient and the response to previous conventional and steroid treatment (Fig. 2) .
Note: our working group recommends consultation with an expert/team of experts to make treatment decisions if there is any uncertainty or in particularly complex cases.
Treatment of cardiomyopathy/shock during acute stage
Myocardial function usually recovers after treatment with IVIG, as the latter curbs inflammation and systemic manifestations. In cases with mild haemodynamic instability, patients usually respond to treatment with diuretic and vasopressor agents. Shock may have a cardiogenic, distributive or mixed cause, with a pathophysiology similar to that of septic shock, with vasodilation produced by inflammatory factors, absolute and relative hypovolaemia and myocardial dysfunction. In these cases, treatment with IVIG should be combined with the use of inotropic and vasopressor agents (dobutamine, epinephrine, norepinephrine and dopamine). 11
Prevention and treatment of thrombosis in patients with coronary aneurisms
In addition to rupture of a coronary artery aneurism, which is a rare occurrence, thrombotic occlusion of a coronary aneurism followed by secondary myocardial infarction is the most frequent complication in the acute stage of KD.
Coronary thrombosis should be suspected in patients with rapid deterioration of ventricular function or electrocardiographic changes. In case of coronary aneurisms with a progressive increase in diameter, the use of antiplatelet agents should be considered (for example, adding clopidogrel to ASA), as inadequate thromboprophylaxis in patients with coronary abnormalities is the strongest predictor of a poor outcome during the acute stage of disease.
The management in this section has been extrapolated from clinical practice in adults with coronary or cerebrovascular disease (Tables 4 and 5 ).
Risk stratification and follow-up
Patients with KD are stratified into different groups according to coronary involvement regardless of the stage of disease. In addition to the size of aneurisms, the risk factors for ischaemia that need to be considered are: extent of maximal involvement, distal location, absence of collateral vessels, obstruction, prior history of thrombosis, acute myocardial infarction (AMI), revascularisation or presence of ventricular dysfunction. The greater the extent of coronary involvement, the higher the risk of developing ischaemia, so the management and follow-up will vary between groups ( Table 6 ). The long-term management protocol should be initiated at the end of the acute stage ( 4 ---6 weeks) when coronary artery luminal diameters are no longer enlarging.
The cardiovascular risk of patients without aneurisms is similar to that of the general population, so these patients may be discharged from follow-up in the cardiology department after verifying the normalisation of coronary artery features, with an emphasis on the evaluation of cardiovascular risk factors. 2 In cases where aneurisms develop, the latter resolve in the first 3 months in 15% of patients, and there is regression from initial measurement in most patients within the next 2 years, depending on the extent of involvement. 38 Despite regression, the aneurismal area may narrow progressively as a result of luminal myofibroblastic proliferation. For this reason, patients that develop aneurisms in the acute stage of KD require long-term cardiologic follow-up, regardless of regression.
Patients with severe coronary artery involvement do not usually develop cardiologic symptoms unless they suffer myocardial ischaemia secondary to obstruction and thrombosis.
The signs and symptoms of AMI may be atypical and nonspecific in children, especially in infants. Few cases of myocardial ischaemia have been reported in children due to the development of collateral vessels, and they have been associated with the rupture of aneurisms during acute illness due to their rapid growth.
In cases where there is evidence of inducible myocardial ischaemia, performance of invasive angiography is Cardiac catheterization in cases with severe stenosis in 5 coronary arteries Coronary artery bypass in cases with severe occlusion in left coronary artery or involvement of 2 or 3 vessels, as long as there is viable myocardium a The cardiologic assessment includes history and physical examination, electrocardiogram and echocardiogram (the latter is not essential in patients with normalisation of the coronary arteries, unless they exhibit symptoms of ischaemia, ventricular dysfunction or inducible ischaemia). b Primary prevention of cardiovascular risk factors includes: measurement of blood pressure, monitoring of body mass index (BMI) and waist circumference, education on healthy dietary habits and prevention of smoking and sedentary lifestyles. In patients with a history of aneurism, performance of a lipid profile every 5 years. Follow-up may be carried out by the primary care paediatrician. c Cardiac stress tests: stress echocardiography, stress magnetic resonance imaging (MRI), stress nuclear medicine (NM) perfusion imaging or positron-emission tomography (PET). The choice of method will be made by each facility based on its experience and minimising patient risk. In children aged <6 years who are asymptomatic, have no symptoms of ischaemia or signs of ventricular dysfunction, consider non-invasive coronary artery imaging at rest. d Coronary angiography can be performed through non-invasive methods (PET, MRI, CT) or invasively (catheterization). In case of inducible ischaemia, catheterization is the method of choice. Coronary angiography should not be performed during the acute stage: defer until at least 6 months from diagnosis. e Severe stenosis is defined as a ≥75% narrowing of the lumen (>50% in case of the left main trunk).
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CONSIDER:
If stable patient with non-severe disease without increase/worsening of high-risk parameters:
Did not receive corticosteroids: 2nd dose of IVIG (2g/kg) + corticosteroid regimen 2.
Received corticosteroids:
2nd dose of IVIG (2g/kg) + corticosteroid regimen 1.
Infliximab/anakinra. Consultation with expert is recommended.
Did not receive corticosteroids: same as 2a.
Received corticosteroids: same as 2b.
Other treatments to consider: etanercept, ciclosporin, cyclophosphamide (Table 5 ), plasma exchange.
Cardiologic checkup 2 times a week until resolution of fever, normalization of symptoms and decrease in CPR levels.5 Then, lower ASA to 3-5 mg/kg/day. Maintain for at least 6 weeks, discontinuing after confirming decrease in platelet count and based on coronary involvement.
If patient has severe disease and increase/worsening of high-risk parameters:
1.
2.
a.
b.
1:
2.
Methylprednisolone boluses: 30 mg/kg/day IV for 3 days followed by methylprednisolone/prednisolone/prednisone (2 mg/kg/day) IV/p.o. based on clinical condition of patient. If IV treatment is required, switch to oral route when fever resolves and CRP level decreases.5 Maintain 2 mg/kg/day dose until CRP normalizes. Taper over 2-3 weeks to discontinuation.3 semanas.
Methylprednisolone at 2 mg/kg/day IV until fever resolves and CRP level decreases,5 followed by prednisolone/prednisone (2 mg/kg/day) p.o. until CRP normalizes. Taper over 2-3 weeks to discontinuation.
Rule out sensorineural hearing loss and presence of anterior uveitis (helps diagnosis in uncertain cases), iridocyclitis, vitreous opacities, subconjunctival haemorrhage, punctate keratitis, papilloedema. 2: some patients require nonsteroidal anti-inflammatory agents, such as ibuprofen, that interfere with the antiplatelet effect of ASA. Consider an alternative antiplatelet agent in these patients ( recommended to assess for coronary stenosis, even if the patient is asymptomatic.
Adult patients with Kawasaki disease
Acute-stage KD does not usually occur in adults. Patients with KD have usually been discharged or are those that have developed sequelae. Their follow-up is planned according to the presence and severity of coronary involvement, past and present, focusing on abnormalities in the coronary arteries, valve function and myocardial abnormalities (function, perfusion and presence of scar tissue) ( Table 6 ). Coronary aneurysms are located at the epicardial level, and the most frequent locations are the proximal segments of the anterior descending artery and right coronary artery, followed by the left main trunk and the circumflex artery, distal segments of the right coronary artery and the posterior descending artery, with a predominance of involvement at branching points.
The long-term mortality of Japanese patients with a history of KD and cardiovascular sequelae is higher compared to the general population. 39 Recent studies have suggested a high incidence of adverse events associated with KD in young adults. In the United States, 5% AMIs in individuals aged less than 40 years occur in patients with a known or suspected history of KD (1.5% and 3.5%, respectively). 40 In Japan, up to 9% of AMIs and sudden cardiac deaths in young adults are attributable to a previous history of KD. 16 The AHA recommends transitioning to adult cardiology care at age 18---21 years. 11 Adult cardiologists must be aware of this growing cohort of young adults at risk of cardiovascular sequelae from their childhood disease, which makes the collaboration between paediatric and adult cardiologists essential.
Note: to participate in the KAWA-RACE study, contact kawasaki.kawarace@gmail.com.
